Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats

Cancer Research

Volumn 57, Issue 10, 1997, Pages 1934-1938

  Chu, Xiao Yan ^a   Kato, Yukio ^a   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; DRUG METABOLITE; GLUCURONIDE; IRINOTECAN;

ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; CANCER CHEMOTHERAPY; CONCENTRATION RESPONSE; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG UPTAKE; LIVER MEMBRANE; LIVER METABOLISM; MALE; MEMBRANE VESICLE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BILIARY TRACT; CAMPTOTHECIN; CARBOXYLIC ACIDS; GLUTATHIONE; HYPERBILIRUBINEMIA; LACTONES; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030906434     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Andoh, T., Ishii, K., and Suzuki, Y. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc. Natl. Acad. Sci. USA, 84: 5565-5569, 1987.
2. Hsiang, Y-H., Liu, L. F., Wall, M. E., Wani, M. C., Nicholas, A. W., Manikumar, G., Kirschenbaum, S., Silber, R., and Potmesil, M. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res., 49: 4385-4389, 1989.
3. Jaxel, C., Kohn, K. W., Wani, M. C., Wall, M. E., and Pommier, Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res., 49: 1465-1469, 1989.
4. Tanizawa, A., Fujimori, A., Fujimori, Y., and Pommier, Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl. Cancer Inst., 86: 836-842, 1994.
5. Ohno, R., Okada, K., Masaoka, T., Kuramoto, A., Arima, T., Yoshida, Y., Ariyoshi, H., Ishimaru, M., Sakai, Y., Oguro, M., Ito, Y., Morishima, Y., Yokomaku, S., and Ota, K. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol., 8: 1907-1912, 1990.
6. Gandia, D., Armand, J., Chabot, G., Abigerges, D., Rougier, P., Ruffile, P., Cote, C., and Mathieu-Boue, A. Phase I study of the new camptothecin analogue CPT-11 administered every 3 weeks. Proc. Am. Assoc. Cancer Res., 33: 260, 1992.
7. Rowinsky, E. K., Grochow, L. B., Ettinger, D. S., Sartorius, S. E., Lubejko, B. G., Chen, T-L., Hendricks, C., Rock, M. K., and Donehower, R. C. Phase I and pharmacological study of novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res., 54: 427-436, 1994.
8. Kudoh, S., Fukuoka, M., Masuda, N., Yoshikawa, A., Kusunoki, Y., Matsui, K., Negoro, S-I., Takifugi, N., Nakagawa, K., Hirashima, T., Yana, T., and Takada, M. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin. Jpn. J. Cancer Res., 86: 406-413, 1995.
9. Negoro S., Fukuoka, M., Masuda, N., Takada, M., Kusunoki, Y., Matsui, K., Takifugi, N., Kudoh, S., Niitani, H., and Taguchi, T. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J. Natl. Cancer Inst., 83: 1164-1168, 1991.
10. Sasaki, Y., Hakusui, H., Mizuno, S., Morita, M., Miya, T., Eguchi, K., Shinkai, T., Tamura, T., Ohe, Y., and Saijo, N. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn. J. Cancer Res., 86: 101-110, 1995.
11. Araki, E., Ishikawa, M., Iigo, M., Koide, T., Itabashi, M., and Hoshi, A. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood, plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn. J. Cancer Res., 84: 697-702, 1993.
12. Narita, M., Nagai, E., Hagiwara, H., Aburada, M., Yokoi, T., and Kamataki, T. Inhibition of β-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate. Xenobiotica, 23: 5-10, 1993.
13. Takasuna, K., Kasai, Y., Kitano, Y. Mori, K. Kobayashi, R., Hagiwara, T., Kakihata, K., Hirohashi, M., Nomura, M., Nagai, E., and Kamataki, T. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloridc (CPT-11), in rats. Jpn. J. Cancer Res., 86: 978-984, 1995.
14. Chu, X-Y., Kato, Y., Niinuma, K., Sudo, K-I., Hakusui, H., and Sugiyama, Y. Multispecific organic anion transporter (cMOAT) is responsible for biliary excretion or the camptothecin derivative irinotecan, CPT-11, and its metabolites in rats. J. Pharmacol. Exp. Ther., in press, 1997.
15. Akerboom, T. P. M., Narayanaswami, V., Kunst, M., and Sies, H. ATP-dependent S-(2,4-dinitrophenyl) glutathione transport in canalicular plasma membrane vesicles from rat liver. J. Biol. Chem., 266: 13147-13152, 1991.
16. Kobayashi, K., Sogame, Y., Hara, H., and Hayashi, K. Mechanism of glutathione S-conjugate transport in canalicular and basolateral rat liver plasma membranes. J. Biol. Chem., 265: 7737-7741, 1990.
17. Inoue, M., Akerboom, T. P. M., Sies, H., Kinne, R., Thao, T., and Arias, I. M. Biliary transport of glutathione S-conjugate by rat liver canalicular membrane vesicles. J. Biol. Chem., 259: 4998-5002, 1984.
18. Ito, K., Suzuki, H., Hirohashi, T., Kume, K., Shimizu., T., and Sugiyama, Y. Expression of a putative ATP-binding cassette region, homologous to that in multidrug resistance-associated protein (MRP), is hereditarily defective in Eisai hyperbilirubinemic rats (EHBR). Int. Hepatol. Commun., 4: 291-298, 1996.
19. Mayer, R., Kartenbeck, J., Büchler, M., Jedlitschky, G., Leier, I., and Keppler, D. Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport-deficient mutant hepatocytes. J. Cell Biol., 131: 137-150, 1995.
20. Paulusma, C. C. Bosma, P. J., Zaman, G. J. R., Bakker, C. T. M., Otter, M., Scheffer, G. E., Scheper, R. J., Borst, P., and Elferink, R. P. J. O. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science (Washington DC), 271: 1126-1128, 1996.
21. Ito, K., Suzuki, H., Hirohashi, T., Kume, K., Shimizu, T., and Sugiyama, Y. Molecular cloning of canalicular multispecific organic anion transporter (cMOAT) whose expression is defective in mutant rats with hereditary conjugated hyperbilirubinemia (EHBR). Am. J. Physiol., 272: G16-G22, 1997.
22. Sathirakul, K., Suzuki, H., Yasuda, K., Hanano, M., Tagaya, O., Horie, T., and Sugiyama, Y. Kinetic analysis of hepatobiliary transport of organic anions in Eisai hyperbilirubinemic mutant rats. J. Pharmacol. Exp. Ther., 265: 1301-1312, 1993.
23. Takenaka, O., Horie, T., Suzuki, H., and Sugiyama, Y. Different biliary excretion systems for glucuronide and sulfate of a model compound: study using Eisai hyperbilirubinemic rats. J. Pharmacol. Exp. Ther., 274: 1362-1369, 1995.
24. Takenaka, O., Horie, T., Kobayashi K., Suzuki, H., and Sugiyama, Y. Kinetic analysis of hepatobiliary transport for conjugated metabolites in the perfused liver of mutant rats (EHBR) with hereditary conjugated hyperbilirubinemia. Pharm. Res. (NY), 12: 1746-1755, 1995.
25. Higgins, C. F. ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol., 8: 67-113, 1992.
26. Sathirakul, K., Suzuki, H., Yamada, T., Hanano, M., and Sugiyama, Y. Multiple transport systems for organic anions across the bile canalicular membrane. J. Pharmacol. Exp. Ther., 268: 65-73, 1994.
27. Shimamura, H., Suzuki, H., Hanano, M., Suzuki, A., Tagaya, O., Horie, T., and Sugiyama, Y. Multiple systems for the biliary excretion of organic anions in rats: Liquiritigenin conjugates as model compounds. J. Pharmacol. Exp. Ther., 271: 370-378, 1994.
28. Cole, S. P. C., Bhardwaj, J., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C. Stewart, A. J., Kurz, E. U., Duncan, A. M. V., and Deeley, R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (Washington DC), 258: 1650-1654, 1992.
29. Loe, D. W., Almquist, K. C. Cole, S. P. C., and Deeley, R. G. ATP-dependent 17β-estradiol 17-(β-D-glucuronide) transport by multidrug resistance protein (MRP). J. Biol. Chem., 271: 9683-9689, 1996.
30. Jedlitschky, G., Leier, I., Buchholz, U., Center, M., and Keppler, D. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res., 54: 4833-4836, 1994.
31. 4 and structurally related conjugates. J. Biol. Chem., 269: 27807-27810, 1994.
32. Müller, M., Mayer, R., Hero, U., and Keppler, D. ATP-dependent transport of amphiphilic cations across the hepatocyte canalicular membrane mediated by mdr1 P-glycoprotein. FEBS Lett., 343: 168-172, 1994.
33. Yamaoka, K., Tanigawara, Y., Nakagawa, T., and Uno, T. A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobio-Dyn., 4: 879-885, 1981.
34. Yamaoka, K., Nakagawa, T., and Uno, T. Application of Akaike's Information Criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm., 6: 165-175, 1978.
35. Kaneda, N., and Yokokura, T. Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res., 50: 1721-1725, 1990.
36. Atsumi, R., Suzuki, W., and Hakusui, H. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica, 21: 1159-1169, 1991.
37. Gupta, E., Safa, A. R., Wang, X., and Ratain, M. J. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. Cancer Res., 56: 1309-1314, 1996.
38. Fassberg, J., and Stella, V. J. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci., 81: 676-684, 1992.
39. Wani, M. C., Nicholas, A. W., Manikumar, G., and Wall, M. E. Plant antitumor agents. 25. Total synthesis and antileukemic activity of ring A substituted camptothecin analogues: structure-activity correlations. J. Med. Chem., 30: 1774-1779, 1987.
40. Slichenmyer, W. J., Rowinsky, E. K., Donehower, R. C., and Kaufmann, S. H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst., 85: 271-291, 1993.
41. Hsiang, Y-H., Hertzberg, R., Hecht, S., and Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260: 14873-14878, 1985.
42. Leier, I., Jedlitschky, G., Buchholz, U., Center, M., Cole, S. P. C. Deeley, R. G., and Keppler, D. ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. Biochem. J., 314: 433-437, 1996.
43. 4 and chemotherapeutic agents in membrane vesicles. J. Biol. Chem., 271: 9675-9682, 1996.
44. Evers, R., Zaman, G. J. R., Deemter, L. V., Jansen, H., Calafat, J., Oomen, L. C. J. M., Elferink, R. P. J. O., Borst, P., and Schinkel, A. H. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J. Clin. Invest., 97: 1211-1218, 1996.